KV Pharma Reaches $12.8M Deal To Settle Shareholder Action
KV Pharmaceutical Co. and the lead plaintiffs in a securities class action alleging the drugmaker hid U.S. Food and Drug Administration violations to inflate its share price have reached a $12.8 million...To view the full article, register now.
Already a subscriber? Click here to view full article